Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

181. [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"]

[Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Systematische leitlinienrecherche und -bewertung sowie extraktion relevanter empfehlungen für ein DMP (...) osteoporose: abschlussbericht; auftrag V14-0 [Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

2016 Health Technology Assessment (HTA) Database.

182. Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency

Alendronic Acid / Colecalciferol Mylan - postmenopausal osteoporosis in women at risk of vitamin D deficiency 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 24 June 2016 EMA/354096/2016 EMEA/H/C/004172 Questions and answers (...) Withdrawal of the marketing authorisation application for Alendronic Acid/Colecalciferol Mylan (alendronic acid and colecalciferol) On 27 May 2016, Mylan SAS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Alendronic Acid/Colecalciferol Mylan, for the treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency. What is Alendronic Acid/Colecalciferol Mylan? Alendronic Acid

2016 European Medicines Agency - EPARs

183. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223157 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096-7 10.1056/NEJMc1602599 Black Dennis M DM Rosen Clifford J CJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2095 27223158 N Engl J Med. 2016 May 26;374(21):2095-6 (...) 27223159 N Engl J Med. 2016 May 26;374(21):2096 27223160 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223157 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA4

2016 NEJM

184. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223158 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095 10.1056/NEJMc1602599 Michaëlsson Karl K Uppsala University, Uppsala, Sweden karl.michaelsson@surgsci.uu.se. Aspenberg Per P Linköping University, Linköping, Sweden. eng 88225-1 CIHR Canada Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med (...) . 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223158 10.1056/NEJMc1602599 PMC5104560 CAMS6243 10.1056/NEJMc1602599#SA1 N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 BMJ. 2015 May 26;350:h2088 26013536 Osteoporos Int. 2016 Jan;27(1):417

2016 NEJM

185. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223159 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2095-6 10.1056/NEJMc1602599 Ott Susan M SM University of Washington, Seattle, WA smott@uw.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density (...) Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223159 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA2

2016 NEJM

186. Postmenopausal Osteoporosis. Full Text available with Trip Pro

Postmenopausal Osteoporosis. 27223160 2016 05 26 2018 12 02 1533-4406 374 21 2016 05 26 The New England journal of medicine N. Engl. J. Med. Postmenopausal Osteoporosis. 2096 10.1056/NEJMc1602599 Cheung Angela M AM University of Toronto, Toronto, ON, Canada angela.cheung@uhn.ca. Papaioannou Alexandra A McMaster's University, Hamilton, ON, Canada. Morin Suzanne S McGill University, Montreal, QC, Canada. Osteoporosis Canada Scientific Advisory Council eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 0 Bone Density Conservation Agents 0 Diphosphonates AIM IM N Engl J Med. 2016 Jan 21;374(3):254-62 26789873 N Engl J Med. 2016 May 26;374(21):2096-7 27223157 Bone Density Conservation Agents therapeutic use Diphosphonates therapeutic use Female Fractures, Bone prevention & control Humans Osteoporosis, Postmenopausal drug therapy 2016 5 26 6 0 2016 5 26 6 0 2016 5 27 6 0 ppublish 27223160 10.1056/NEJMc1602599 10.1056/NEJMc1602599#SA3

2016 NEJM

187. Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis Full Text available with Trip Pro

Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis To investigate the correlation between serum Omentin-1 levels and the presence of osteoporosis in older men.Serum Omentin-1, bone turnover biochemical markers, and bone mineral density (BMD) were determined in 45 older men with osteoporosis or 45 older men without osteoporosis (65-70 years old).Omentin-1 levels were increased in older men with osteoporosis, and the differences remained (...) with osteoporosis and control groups that were considered separately.Omentin-1 is an independent predictor of BMD in older men with osteoporosis, and it is negatively correlated with bone turnover biochemical markers. It is suggested that Omentin-1 may exert a negative effect on bone mass through the regulation of the osteoblast differentiation in the older men with osteoporosis.

2016 Chronic diseases and translational medicine

188. Treatment for osteoporosis in people with ß-thalassaemia. Full Text available with Trip Pro

Treatment for osteoporosis in people with ß-thalassaemia. Osteoporosis is a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis represents an important cause of morbidity in people with beta-thalassaemia and its pathogenesis is multifactorial. Factors include bone marrow expansion due to ineffective erythropoiesis, resulting in reduced trabecular (...) bone tissue with cortical thinning; endocrine dysfunction secondary to excessive iron loading, leading to increased bone turnover; and lastly, a predisposition to physical inactivity due to disease complications with a subsequent reduction in optimal bone mineralization.A number of therapeutic strategies have been applied to treat osteoporosis in people with beta-thalassaemia, which include bisphosphonates, with or without, hormone replacement therapy. There are various forms of bisphosphonates

2016 Cochrane

189. Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis. (Abstract)

Comparison of unilateral versus bilateral percutaneous kyphoplasty for the treatment of patients with osteoporosis vertebral compression fracture (OVCF): a systematic review and meta-analysis. To compare the short- and long-term clinical outcomes, operation times, restoration rate, dosage of polymethylmeth-acrylate (PMMA) injected, complications and X-rays exposure frequency between unilateral and bilateral kyphoplasty approaches for the treatment of OVCF.Systematic review and meta

2016 European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

190. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 22 (Suppl 4) September 2016 1 AACE/ACE Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016 Pauline M. Camacho, MD, FACE; Steven M. Petak, MD, MACE (...) University Osteoporosis and Metabolic Bone Disease Center, Chicago, IL; 2 Associate Clinical Professor Weill-Cornell Medical College, Division Head Endocrinology and Chief of Endocrinology, Houston Methodist Hospital, Houston, TX; 3 School of Medicine and Public Health, University of Wisconsin, Madison, WI; 4 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN; 5 Clinical Professor of Medicine, University of California, San Francisco; 6 Division of Endocrinology

2016 American Association of Clinical Endocrinologists

191. Osteoporosis and Bone Mineral Density

Osteoporosis and Bone Mineral Density Date of origin: 1998 Last review date: 2016 ACR Appropriateness Criteria ® 1 Osteoporosis and Bone Mineral Density American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Osteoporosis and Bone Mineral Density Variant 1: Asymptomatic BMD screening or individuals with established or clinically suspected low BMD. 1. All women age 65 years and older and men age 70 years and older (asymptomatic screening) 2. Women younger than age 65 (...) years who have additional risk for osteoporosis, based on medical history and other findings. Additional risk factors for osteoporosis include: a. Estrogen deficiency b. A history of maternal hip fracture that occurred after the age of 50 years c. Low body mass ( 1 year before age 42 years) 3. Women younger than age 65 years or men younger than age 70 years who have additional risk factors, including: a. Current use of cigarettes b. Loss of height, thoracic kyphosis 4. Individuals of any age

2016 American College of Radiology

192. Association of interleukin-6 gene polymorphism and osteoporosis in postmenopausal women: a systematic review and meta-analysis

Association of interleukin-6 gene polymorphism and osteoporosis in postmenopausal women: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

193. The potential effect of Wuqinxi exercise for primary osteoporosis: a systematic review and meta-analysis

The potential effect of Wuqinxi exercise for primary osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2016 PROSPERO

194. Osteoporosis and bone fractures in polycystic ovary syndrome: a systematic review and meta-analysis

Osteoporosis and bone fractures in polycystic ovary syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2016 PROSPERO

195. Medication-related osteonecrosis of the jaw associated with antiresorpative drugs in osteoporosis: a systematic review protocol

Medication-related osteonecrosis of the jaw associated with antiresorpative drugs in osteoporosis: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

196. Combination therapy of anabolic agents and bisphosphonates for bone mineral density in patients with osteoporosis: a meta-analysis of randomized controlled trials

Combination therapy of anabolic agents and bisphosphonates for bone mineral density in patients with osteoporosis: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2016 PROSPERO

197. Facilitators and barriers to exercise adherence in patients with osteoporosis: a systematic review

Facilitators and barriers to exercise adherence in patients with osteoporosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2016 PROSPERO

198. Warming needling in primary osteoporosis management: a systematic review and meta-analysis

Warming needling in primary osteoporosis management: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

199. Moxibustion treatment for primary osteoporosis: a systematic review of randomized controlled trials

Moxibustion treatment for primary osteoporosis: a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2016 PROSPERO

200. Proton pump inhibitor therapy and risk of osteoporosis and fracture: a systematic review and meta-analysis

Proton pump inhibitor therapy and risk of osteoporosis and fracture: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO